title: Immunosuppression-associated lymphoproliferative disorders in rheumatic patients.
abstract: The association between rheumatic disease and the occurrence of hematolymphoid neoplasms has been a subject of investigation for many years. Recently, we and others have reported the development in rheumatic patients of lymphoproliferative disorders that are similar to those occurring in patients with known immunocompromised states. The lymphoid neoplasms that develop in patients with immunosuppression are characterized by several features including the presence of EBV genome in the neoplastic cells. The fact that lymphomas with features of those occurring in immunosuppressed patients can occur in patients with rheumatic disease suggests that immune system impairment secondary to the rheumatic disease, the treatment given for the rheumatic disease, or to a combination of these factors, might play a role in the development of lymphoma in these patients. This review will first describe the characteristics of lymphoproliferative disorders that occur in patients with known immunocompromised states. It will then review general aspects of lymphomas in rheumatic patients with a focus on more recent reports that have described the development of immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Studies that investigate the relative contribution of the rheumatic disease versus therapy for rheumatic disease in the development of lymphoma in this patient group are still needed.
authors.affiliation: Department of Pathology, Stanford University Medical Center, California 94305, USA.
authors.forename: O W
authors.initials: OW
authors.lastname: Kamel
authors.forename: M
authors.initials: M
authors.lastname: van de Rijn
authors.forename: M M
authors.initials: MM
authors.lastname: Hanasono
authors.forename: R A
authors.initials: RA
authors.lastname: Warnke
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000473:pathology / Q000821:virology; D005260:Female; D005500:Follow-Up Studies; D006566:Herpesviridae Infections / Q000150:complications; D004854:Herpesvirus 4, Human / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008223:Lymphoma / Q000145:classification / Q000453:epidemiology / Q000209:etiology / Q000276:immunology / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000276:immunology / Q000821:virology; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000150:complications* / Q000276:immunology; D012306:Risk; D012859:Sjogren's Syndrome / Q000150:complications / Q000276:immunology; D014412:Tumor Virus Infections / Q000150:complications
chemical_list: D008727:Methotrexate